drugset / Trial / NCT02616393
Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases
Non-randomizedSingle-groupOpen-labelTreatment
Summary
A study to assess the activity of tesevatinib in subjects with non-small cell lung cancer (NSCLC) and activating epidermal growth factor receptor (EGFR) mutations who have disease progression with Brain Metastases (BM) or Leptomeningeal Metastases (LM) or who have either BM or LM at initial presentation (IP)
Timeline
- Start
- 2015-11
- Primary completion
- 2018-04-03
- Completion
- 2018-04-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tesevatinib | Small molecule | 300 mg | Oral |